J. Szamosi

发表

Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.

E. Constant, M. Bauer, M. Brecher, 2009, The Journal of clinical psychiatry.

Multiple Dose Pharmacokinetics of a New Once Daily Extended Release Tolterodine Formulation Versus Immediate Release Tolterodine

B. Olsson, J. Szamosi, 2001, Clinical pharmacokinetics.

PMH72 The Impact of Once-Daily Extended-Release Quetiapine Fumarate (Quetiapine XR) on Length of Hospitalisation of Patients with Acute Bipolar Mania

P. Wahlqvist, M. Bonafede, H. Eriksson, 2011 .

Food Does Not Influence the Pharmacokinetics of a New Extended Release Formulation of Tolterodine for Once Daily Treatment of Patients with Overactive Bladder

B. Olsson, J. Szamosi, 2001, Clinical pharmacokinetics.

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study

J. Oldenburg, V. Jiménez‐Yuste, S. Lethagen, 2019, BMJ Open.

Real‐world prophylactic usage of recombinant factor IX Fc in Sweden: A report from the Swedish National Registry for bleeding disorders

Linda Myrin Westesson, J. Astermark, F. Baghaei, 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

Real‐world prophylactic usage of recombinant factor VIII Fc in Sweden: A report from the Swedish national registry for bleeding disorders

J. Astermark, M. Holmström, M. Axelsson, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B

M. Ozelo, S. Lethagen, K. Pasi, 2018, Research and practice in thrombosis and haemostasis.

A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder.

M. Bauer, H. Eriksson, C. Datto, 2010, Journal of affective disorders.

Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study

M. Bourin, P. Gass, E. Severus, 2014, International Journal of Bipolar Disorders.

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria afte

Andrea Zatkova, Annalisa Santucci, Daniela Braconi, 2014, Annals of the rheumatic diseases.

Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.

J. Jarvis, L. Ranganath, B. Olsson, 2020, The lancet. Diabetes & endocrinology.

Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.

M. Couce, C. Dionisi-Vici, A. Lund, 2021, The lancet. Diabetes & endocrinology.

Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant

M. Thase, G. Dunbar, D. Hosford, 2014, European Neuropsychopharmacology.

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8‐week placebo‐controlled studies

Dan J Stein, B. Bandelow, H. Eriksson, 2011, Human psychopharmacology.

Impact of once-daily extended-release quetiapine fumarate on hospitalization length in patients with acute bipolar mania.

P. Wahlqvist, M. Bonafede, H. Eriksson, 2015, Journal of comparative effectiveness research.

Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study

A. Lazarus, R. Weisler, H. Eriksson, 2009, CNS Spectrums.

Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.

L. Ranganath, B. Olsson, A. Milan, 2015, JIMD reports.

Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies

S. Montgomery, A. Lazarus, R. Weisler, 2012, International clinical psychopharmacology.

Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels

A. Altamura, S. Montgomery, H. Eriksson, 2014, International clinical psychopharmacology.

Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder.

R. McIntyre, M. Bauer, S. Montgomery, 2013, Journal of affective disorders.

Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment

M. Thase, K. Demyttenaere, M. Bauer, 2014, International clinical psychopharmacology.

Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy.

R. McIntyre, M. Bauer, H. Eriksson, 2013, The international journal of neuropsychopharmacology.

Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.

M. Trivedi, K. Demyttenaere, B. Bandelow, 2013, The international journal of neuropsychopharmacology.

once daily nitisinone on 24-hour urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment

Martina, J. Jarvis, L. Ranganath, 2015 .

Safety and Tolerability of Dexmecamylamine (TC-5214) Adjunct to Ongoing Antidepressant Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy: Results of a Long-Term Study

G. Dunbar, D. Hosford, H. Eriksson, 2015, Journal of clinical psychopharmacology.

Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy

H. Möller, G. Dunbar, K. Demyttenaere, 2015, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.